How many clinical trials are tracked for Kidney Diseases?

26 trials are tracked, 1 with published results.

Kidney Diseases Research

Kidney Diseases: what the trials found

Clinical evaluations of transplant and management interventions show varied outcomes for kidney health. Campath demonstrated a one-year survival rate with a functioning graft of 97.6% and 95.1% (p=0.467), while the occurrence of rejection episodes was recorded at 91.2% and 82.3% (p=0.138) ². In studies involving growth stimulation, a combination of Tacrolimus, Mycophenolate Mofetil, and Prednisone withdrawal resulted in a delta Z-score of 1.2 and 0.6 after 12 months ⁸.

Pharmacological interventions for renal function include enteric-coated mycophenolate sodium (EC-MPS), which showed no treatment failures (BPAR, graft loss, death, or loss to follow-up) at 6 months across all study arms ⁹. Other established interventions in the clinical landscape include Regadenoson ⁵, MB-102 ⁶, and Omega-3 fatty acids ⁷. Additionally, H.P. Acthar Gel was evaluated with protein/creatinine ratios of 3.1, 3.1, 2.4, and 1.6 ³.

Monitoring and supportive technologies have been established in clinical settings, including the Vigileo Monitor ⁴.

For the clinician treating this condition

EC-MPS demonstrated high safety and efficacy at 6 months, with zero instances of treatment failure including biopsy-proven acute rejection or graft loss ⁹.
Campath showed a high one-year survival rate for functioning grafts (97.6% and 95.1%) ².
A combination of Tacrolimus and Mycophenolate Mofetil with Prednisone withdrawal was associated with growth stimulation over 12 months ⁸.

AI synthesis of 9 cited trials, updated Jun 24, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

Kidney Diseases: current evidence & treatments

Multiple studies address diagnostic and prognostic markers in kidney diseases. Cystatin C demonstrates good diagnostic performance for early detection of sepsis-associated acute kidney injury (SA-AKI) with an AUC of 0.88, sensitivity 0.81, and specificity 0.82 ¹. In diabetic kidney disease (DKD), prediction models for progression to end-stage renal disease show pooled AUCs of 0.896 in training and 0.863 in validation sets ²⁴. Fibroblast growth factor 23 (FGF23) levels are markedly elevated in DKD patients compared to controls (SMD 1.144) ²⁵. Additionally, leukocyte telomere length is shorter in chronic kidney disease (CKD) patients and correlates positively with eGFR ¹¹. Shared genetic loci between pediatric steroid-sensitive nephrotic syndrome and IgA nephropathy have been identified via meta-analysis ¹³.

Therapeutic interventions show varied benefits. Semaglutide reduces the risk of kidney decline or death in type 2 diabetes and CKD ³. In kidney transplant recipients, steroid avoidance may reduce all-cause death and post-transplant diabetes but increases rejection risk ⁶. For kidney stones, endoscopic combined intrarenal surgery (ECIRS) triples stone-free odds compared to percutaneous nephrolithotomy (PCNL) for large stones ¹⁰, while fluoroless ultrasound-guided techniques lower complications in PCNL with equivalent stone-free rates ⁹. Jinlida Granule reduces serum creatinine and HbA1c in DKD patients ⁵. Nutritional vitamin D supplementation in hemodialysis patients reduces C-reactive protein and improves albumin ¹⁷. Cerivastatin is most effective for total cholesterol reduction, and simvastatin for LDL-C in DKD with hyperlipidemia ¹⁶.

Several studies highlight risk factors and complications. Systemic lupus erythematosus (SLE) patients have a 2- to 3-fold higher risk of intracerebral hemorrhage ². Prenatal NSAID exposure is associated with increased kidney disease risk in children (aOR 2.40) ²³. Gut microbiota dysbiosis is linked to sepsis-associated AKI ⁴ and CKD complications via the microbiota-gut-kidney axis [7,14]. Complement activation is a convergent mechanism in AKI ²². Exosomes show promise as biomarkers and therapeutic vectors in diabetic complications ¹⁵. Education and behavior interventions reduce caregiver burden in CKD ¹². Kidney transplantation reduces left-ventricular mass index by 22 g/m² in end-stage kidney disease ⁸.

Cystatin C has good diagnostic accuracy for SA-AKI (AUC 0.88) ¹.

Semaglutide reduces kidney decline or death in type 2 diabetes and CKD ³.

ECIRS triples stone-free odds vs PCNL for large kidney stones ¹⁰.

Prenatal NSAID exposure increases childhood kidney disease risk (aOR 2.40) ²³.

Steroid avoidance in kidney transplant reduces death and diabetes but raises rejection risk ⁶.